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Abstract
Purpose Positron-emission tomography can be useful in on-
cology for diagnosis, (re)staging, determining prognosis, and
response assessment. However, partial-volume effects hamper
accurate quantification of lesions <2–3× the PET system’s
spatial resolution, and the clinical impact of this is not evident.
This systematic review provides an up-to-date overview of
studies investigating the impact of partial-volume correction
(PVC) in oncological PET studies.
Methods We searched in PubMed and Embase databases ac-
cording to the PRISMA statement, including studies from
inception till May 9, 2016. Two reviewers independently
screened all abstracts and eligible full-text articles and per-
formed quality assessment according to QUADAS-2 and
QUIPS criteria. For a set of similar diagnostic studies, we
statistically pooled the results using bivariate meta-regression.
Results Thirty-one studies were eligible for inclusion.
Overall, study quality was good. For diagnosis and nodal
staging, PVC yielded a strong trend of increased sensitivity
at expense of specificity. Meta-analysis of six studies investi-
gating diagnosis of pulmonary nodules (679 lesions) showed
no significant change in diagnostic accuracy after PVC
(p = 0.222). Prognostication was not improved for non-small
cell lung cancer and esophageal cancer, whereas it did im-
prove for head and neck cancer. Response assessment was
not improved by PVC for (locally advanced) breast cancer
or rectal cancer, and it worsened in metastatic colorectal
cancer.
Conclusions The accumulated evidence to date does not sup-
port routine application of PVC in standard clinical PET prac-
tice. Consensus on the preferred PVC methodology in onco-
logical PET should be reached. Partial-volume-corrected data
should be used as adjuncts to, but not yet replacement for,
uncorrected data.
Keywords Pet . Partial-volume effect . Partial-volume
correction . Oncology . Quantification
Introduction
Positron-emission tomography (PET) enables in vivo assess-
ment of metabolic and intracellular processes. Whereas in
clinical practice, PET is predominantly used to qualitatively
assess tracer uptake, PET(/computed tomography [CT]) may
also serve as a surrogate quantitative biomarker of, for exam-
ple, tumor metabolism and proliferation. The application of
quantitative tumor assessment methods for distinguishing be-
nign from malignant lesions, staging, prognostication, and
determining or predicting response to therapy has garnered
increasing interest [1–4].
Accurate quantification of metabolic volumes <2–3× the
spatial resolution of PET is hampered by partial-volume
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effects, leading to underestimations of standardized uptake
value (SUV), and possibly compromising lesion detection
[5, 6]. Many methods for partial-volume correction (PVC)
have been advocated [7]. The simplest technique uses recov-
ery coefficients (RC) obtained from phantom experiments un-
der the assumption that true metabolic volume is known and
that lesions are spherically shaped with homogeneous uptake.
More sophisticated methods have been developed, but all suf-
fer from limitations [7, 8]. Voxel-wise resolution recovery
methods, incorporating the point spread function (PSF) within
iterative reconstruction [9] (PSF reconstruction) or performing
post-reconstruction iterative deconvolution [10], could im-
prove both qualitative and quantitative reads. To date, consen-
sus on standardized application of PVC in oncological PET/
CT studies is lacking, and perhaps as a consequence PVC is
not yet routinely applied. In fact, most current clinical quanti-
tative PETstudies merely exclude small lesions (e.g. <2 cm in
diameter), as recommended in the PET Response Criteria in
Solid Tumors (PERCIST) criteria [3].
The clinical impact of PVC in an oncological setting, and
thus the need for standardized application, is not yet fully
elucidated [7]. We performed a systematic review and meta-
analysis to assess the impact of PVC in clinical PET studies,




This systematic review was conducted in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) statement. A comprehensive search
(Supplemental Tables 1 and 2), in collaboration with amedical
librarian (LJS), was performed in PubMed and Embase.com
from inception to May 9, 2016. Both controlled terms (MesH
in PubMed, Emtree in Embase) and free-text terms were in-
cluded in the search. The following were used (including syn-
onyms and closely related words) as index terms or free-text
words: ‘positron-emission tomography or ‘PET’ and ‘partial
volume correction’ or ‘point spread function reconstruction’
and ‘neoplasms’ or ‘cancer’.
Selection process
Abstracts and titles of all studies retrieved from the search
were independently screened by two researchers (MCFC
and GMK). Afterwards, eligible articles were studied in full
text. In case of differences in judgment, consensus was
reached through discussion. Cross-referencing was performed
to further identify relevant articles.
The following were included: studies applying PVC in
clinical PET studies, using oncological patients, reporting
PET data with and without PVC, and investigating clinical
impact of PVC on either diagnosis, staging, prognostication
(reporting survival data), or response assessment.
Exclusion criteria were as follows: reviews, letters, edito-
rials, conference abstracts, case reports, full text not available
or not in English, no adequate reference data, no description of
or reference to PVC method, combined PVC and motion blur
correction method, or patient cohort overlapping with another
included study.
Quality assessment
The quality of included articles was assessed (independently
by MCFC and GMK) according to the QUADAS-2 [11]
(n = 25) or QUIPS [12] (n = 12) tools. QUADAS-2 assesses
bias and applicability of diagnostic studies, whereas QUIPS
assesses bias of studies investigating prognostic factors.
Staging and response assessment studies were assigned to
either of the quality assessment tools. Consensus was reached
through discussion.
Data extraction and meta-analysis
Both researchers independently extracted results regarding
impact of PVC on diagnostic accuracy (for diagnosis and
staging), prediction of survival (for prognostication), and re-
sponse assessment. Measures of diagnostic accuracy were de-
rived with and without PVC. If test characteristics were de-
scribed for subgroups, overall measures of accuracy were cal-
culated when possible. When p-values of differences in accu-
racy between uncorrected and PVC data were not reported,
these differences were deemed not statistically significant.
Descriptive data regarding cancer type, number of patients,
lesion sizes, scanner type, and PVCmethod were also extract-
ed. Unless stated otherwise, we presented data on SUV
quantification.
Diagnostic studies on the same topic were pooled using
bivariate random effects meta-regression analysis, which is
the recommended method for meta-analysis of diagnostic
studies [13]. This method provides summary estimates of sen-
sitivity and specificity with 95% confidence intervals, taking
into account the correlation between sensitivity and specificity
and heterogeneity in results between studies. We tested for
differences in overall diagnostic accuracy between different
diagnostic tests using a likelihood ratio test, comparing
models that included and excluded a covariate for the diag-
nostic test. For illustrative purposes, summary receiver oper-
ating characteristic (ROC) curves were calculated according
to the Moses-Littenberg method [14]. We used Stata software
(version 14; StataCorp LP, College Station, TX) for statistical
analyses.
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Results
Study selection
Pubmed and EMBASE searches yielded 371 potentially eligible
studies (Fig. 1). Three additional studies were found through
reference screening. Two hundred and ninety-three abstracts
were excluded based on eligibility criteria, leaving 81 for full-
text screening. For 19 (5.1%) abstracts, judgments were conflict-
ing, and consensus was reached through discussion. After full-
text review, 31 studies met eligibility criteria (Fig. 1). Studies on
diagnosis (n = 10), staging (n = 10), prognostication (n = 6), and
response assessment (n = 5) are presented in Tables 1, 2, 3, and
4, respectively. Supplemental Table 3 contains the PVC and
tumor delineation methodologies, reconstruction settings, full-
width-at-half-maximumvalues, and voxel sizes of each included
study. Thirty studies used 18F-FDG as radiopharmaceutical, one
study used 18F-choline.
Quality assessment
For extensive descriptions of the QUADAS-2 and QUIPS
scoring criteria, we refer to their respective primary publica-
tions [11, 12].
Considering QUADAS-2 (Fig. 2a), the ‘reference stan-
dard’ and ‘patient selection’ items resulted in low risk of bias
(high risk of bias in 14% of studies for either item). Elevated
risk of bias for the ‘reference standard’ itemwas caused by use
of multiple reference tests within the same study. Risk of bias
in the index test was high in 24% of studies due to the use of
data-driven instead of pre-defined SUV cut-offs. Applicability
concerns regarding patient selection were mainly caused by
large tumor size spectra and unspecified tumor sizes.
Using QUIPS (Fig. 2b), low risk-of-bias scores were found
in the majority of the studies for the items measurement of
outcome and prognostics factors, study attrition, and statistical
analysis and reporting. Several studies did not adequately in-
vestigate potential factors of study confounding, which result-
ed in a moderate risk of bias in 40% of studies and high risk of
bias in 40% of studies. Unclear descriptions of included pa-
tient cohorts (‘study participation’ item) resulted in moderate
risk of bias in 40% of included studies.
Diagnosis
Impact of PVC on diagnosis (Table 1, n = 10) was investigated
for pulmonary nodules (n = 6), breast lesions (n = 1), and
lymphoma (n = 3). PVC included the RC method (n = 9)
Fig. 1 PRISMA flowchart
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and CT volume-based PVC (n = 1). All studies reported lesion
sizes. One study stratified both uncorrected and PVC data for
lesion size in secondary analysis.
The six studies evaluating diagnostic accuracy of PET for
pulmonary nodules were pooled (Table 1, Figs. 3 and 4), and
included a total of 352 malignant and 327 benign lesions
[17–21, 23]. Prevalence of malignancy ranged from 27 to
77% (mean 57%). Five studies applied an RC method for
PVC, one study applied a CT volume-based correction.
Thresholds of PET positivity were predefined in 5/6 studies
and data-driven in 1/6 studies. Predefined thresholds were
similar for uncorrected and PVC data. Three studies used
SUV 2.5 as predefined threshold [19, 20, 23]. One study used
SUV 2.0 and 2.5 as thresholds [17]. One study used SUV 1.5,
2.0, 2.5, and 3.0 as thresholds [18]. In case of multiple
predefined thresholds, results of the SUVmax 2.5 threshold
were used in meta-analysis (SUVmean for PVC data in
Hickeson et al.) since this was reported in all 5 studies with
predefined SUV thresholds. One study used data-driven
thresholds specifically for uncorrected (SUV 2.4) and PVC
data (SUV 2.9) [21]. Pooled sensitivity and specificity of un-
corrected data were 81% (95% CI 70–89) and 70% (95% CI
48–86), respectively (Fig. 5). Pooled sensitivity and specific-
ity of partial-volume-corrected data were 91% (95% CI 83–
95) and 60% (95% CI 37–79), respectively (Fig. 4). No sig-
nificant change in diagnostic accuracy after PVC was found
(p = 0.222), using the SUV thresholds as described above.
One of the pulmonary studies (by Hickeson et al.) stratified
both uncorrected and corrected data for lesion size [18]. The
authors observed that for lesions <2 cm, accuracy increased
from 59 to 85% using an SUV cut-off 2.5, while for lesions
>2 cm, accuracy changed from 95 to 100%.
With diagnosis of breast lesions, using data-driven
SUVmean thresholds of 2.1 for PVC and non-PVC, at a fixed
specificity of 90%, PVC increased sensitivity from 69 to 81%,
but the impact on accuracy was not statistically significant
[15]. In discriminating between aggressive and indolent non-
Hodgkin lymphoma (NHL), PVC decreased specificity with-
out affecting sensitivity [22]. Similarly, PVC did not improve
differentiation between high- and low-grade NHL [16]. PVC
also enabled differentiation between indolent NHL and
Kikuchi-Fujimoto disease [24].
Staging
Studies evaluating the effect of PVC on staging (Table 2,
n = 10) included lung (n = 3), breast (n = 2), thyroid (n = 1),
head and neck squamous cell (n = 1), nasopharyngeal (n = 1),
prostate (n = 1), and colorectal cancer (n = 1). Applied PVC
methods included the RC method (n = 4), PSF reconstruction
(n = 4), iterative deconvolution (n = 1) and geometric transfer
matrix (n = 1). Most of these studies did not specify SUV
Table 3 Eligible studies evaluating prognostication, in chronological order
Ref. No. of patients Cancer type No. of lesions Spectrum of tumor sizes (mm)a Effect on prognostication?
[35] 145 NSCLC NS Median 30 (range 10–110) Not improved
[36] 52 Esophageal NS NS Not improved
[37] 50 Esophageal NS 39.9 ± 36.1 mL Not improved
[38] 191 NSCLC NS Median 23 (range 10–36) Not improved
[39] 19 HNC 19 15.2 ± 5.0 Improved
[40] 19 HNC 19 15 ± 5 Improved for subgroup
NSCLC non-small cell lung cancer, mLN lymph node metastases, HNC head and neck cancer, NS not specified
a Sizes are presented as mean ± SD, unless stated otherwise
Table 4 Eligible studies evaluating response assessment, in chronological order
Ref. No. of patients Cancer type No. of lesions Spectrum of tumor sizes (mL)a Reference test Effect on response assessment?
[41] 35 LABC NS NS Clinical + pathologic Not improved
[42] 51 Breast NS Median 14 (range 2–227) Pathologic Not improved
[43] 28 LARC NS Median 23 (range 2–397) Pathologic Not improved
[44] 40 mCRC 101 34.4 ± 66.4 RECIST Worsened
[45] 19 NSCLC 24 Median 6.95 (range 2.2–46) Clinical PERCIST classification improved
in 5 lesions, confirmed in follow-up
LABC locally advanced breast cancer, LARC locally advanced rectal cancer, NSCLC non-small cell lung cancer, mCRC metastatic colorectal cancer,
RECIST Response Evaluation Criteriain Solid Tumors, PERCIST PET Response Criteria in Solid Tumors, NS not specified
a Sizes are presented as mean ± SD, unless stated otherwise, at baseline
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thresholds of test positivity for uncorrected and PVC data.
Four studies did not specify lesions sizes. One study stratified
both uncorrected and PVC data for lesion size in secondary
analysis.
In non-small cell lung cancer (NSCLC) patients the asso-
ciation between primary tumor SUVmax and overall TNM
stage disappeared after PVC [25]. For nodal staging using
SUV, non-significant trends of increased accuracy for breast,
head and neck squamous cell, and thyroid cancer (from 80%,
66% and 95% to 84%, 71% and 100%, respectively) [26, 27,
31], and decreased accuracy for nasopharyngeal and prostate
cancer (from 84% and 85% to 73% and 80%, respectively)
were observed [32, 33]. The study investigating accuracy of
nodal staging of nasopharyngeal cancer did observe a large
increase in accuracy, from 14 to 71%, when stratifying for
lesion size (6–7 mm diameter) [32].
With visual image interpretation, PSF reconstruction
tended to increase accuracy of nodal staging in NSCLC,
breast, and colorectal cancer (not statistically significant) com-
pared to non-PSF reconstruction (from 76%, 76%, and 89% to
84%, 80%, and 92%, respectively) [28, 30, 34]. Another study
found no significant difference in lung cancer (several types)
overall staging accuracy between non-PSF and PSF recon-
struction [29].
Fig. 2 Results of quality
assessment according to
QUADAS-2 (a) and QUIPS (b)
tools
Fig. 3 Forest plots presenting sensitivity (a) and specificity (b) with 95% CI of discrimination between benign and malignant pulmonary nodules with
18F-FDG-PET
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Prognosis
Impact of PVC on prognostication (Table 3, n = 6) was inves-
tigated for NSCLC (n = 2), esophageal (n = 2), and head and
neck cancer (n = 2). Applied PVC methods were the RC
method (n = 4), iterative deconvolution (n = 1), and mask-
based PVC (n = 1). Only prognostic studies providing survival
data were included. One study did not specify lesion sizes.
None of the studies stratified results on PVC for lesion size
in secondary analysis.
PVC did not alter the association of SUVmax with
disease-free survival of NSCLC (various histological
types) patients in multivariate analysis [35, 38]. Similarly,
in NSCLC patients (various histologic types), PVC did not
alter the ROC area under the curve of primary tumor
SUVmax to differentiate between groups of patients in
terms of disease-free and overall survival [38]. Primary
tumor SUVs, regardless of PVC, were insufficient as prog-
nostic markers in esophageal (adeno- and squamous cell)
cancer in univariate and ROC analysis [36, 37]. In head
and neck cancer patients, partial-volume-corrected SUV
was significantly different between patient groups strati-
fied according to disease-free survival, whereas uncorrect-
ed SUV was not [39]. In univariate analysis, PVC did not
affect predictive value of head and neck cancer primary
tumor SUV on local recurrence-free survival, distant
metastasis-free survival, and disease-free survival, but did
allow for prediction of distant metastasis-free survival in a
subgroup of patients with PET-positive lymph nodes [40].
Fig. 4 Summary ROC curves of discrimination between benign and
malignant pulmonary nodules with 18F-FDG-PET
Fig. 5 Summary sensitivity and
specificity with 95% confidence
region of discrimination between
benign and malignant pulmonary
nodules with 18F-FDG-PET
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Response assessment
Impact of PVC on response assessment (Table 4, n = 5) was
investigated for breast (n = 2), rectal (n = 1), colorectal (n = 1),
and NSCLC (n = 1). Applied PVC methods included the RC
method (n = 2), iterative deconvolution (n = 2), and both RC
method and iterative deconvolution (n = 1). One study did not
specify lesion sizes. None of the studies stratified results on
PVC for lesion size in secondary analysis.
For locally advanced breast cancer [41], regardless of PVC
primary tumor FDG, metabolic rate was not able to differentiate
between clinical and pathologic responders and non-responders
during neoadjuvant chemotherapy (after 2 months). In another
study in breast cancer patients PVC did not significantly change
prediction of pathologic response with primary tumor SUV dur-
ing neoadjuvant therapy (after two cycles) [42]. In locally ad-
vanced rectal cancer patients treated with (preoperative) chemo-
radiotherapy, PVC had no impact on histopathological response
prediction, at baseline or after 1 or 2 weeks of therapy [43]. In
patients with metastatic colorectal cancer PVC significantly re-
duced the ROC area under the curve of SUV in discriminating
between responders and non-responders after 2 weeks of che-
motherapy, as defined with RECIST [44]. In NSCLC patients
treated with radio- or radiochemotherapy, PVC changed
PERCIST [3] classification of response in 5/24 lesions, which
were verified as correct alterations in clinical follow-up [45].
Discussion
Quantification of functional tumor characteristics with PET is
considered to be useful in clinical oncology, and often uses
semi-quantitative analyses, resulting in SUVs. Unfortunately,
partial-volume effects are known to cause underestimation of
tumor activity, and hence the necessity of PVC for accurate
semi-quantitative reads for small lesions is well recognized
[5]. However, many factors affect its accuracy and potentially
hamper its optimal usage. Perhaps as a consequence, its
resulting advantage in oncological PET studies is not yet ev-
ident. Additionally, the lack of consensus on the preferred
PVC and delineation method may result in suboptimal results
and could hamper comparisons between studies. This review
discusses the clinical impact of PVC and provides recommen-
dations for specific research questions and analyses to be in-
cluded in future studies applying PVC.
When applied to diagnosis of primary lesions and (mainly
nodal) staging, PVC often yielded higher sensitivity at the
expense of specificity (Tables 1 and 2 and Figs. 3 and 4),
which is an obvious consequence when using the same test
positivity SUV thresholds for uncorrected and PVC data. In
the subset of studies which allowed statistical pooling (679
lesions), meta-analysis showed that PVC did not significantly
alter the overall diagnostic accuracy in characterizing
pulmonary lesions with PET (Fig. 5). When estimating the
effect of PVC, the optimal trade-off between sensitivity and
specificity (the SUV threshold of test positivity) may be dif-
ferent for PVC and uncorrected data. At an exploratory level,
one should define this cut-off for either method. Of note,
Degirmenci et al. (on pulmonary nodules) used data-driven
SUV cut-offs of 2.4 and 2.9 for uncorrected and PVC data,
respectively, which yielded a specificity fixed at 80%, with
sensitivity of 62 and 73% for uncorrected and PVC data, re-
spectively [21]. We performed a similar analysis using the
(individual patient) data from Hickeson et al. [18]. At a
predefined SUV cut-off of 2.5, PVC decreased specificity
and increased sensitivity (Table 1). However, when applying
cut-offs of 2.55 and 2.8 (as derived from ROC analysis) for
uncorrected and PVC data, respectively, PVC increased sen-
sitivity from 72 to 94%, while specificity remained constant at
91%. This further demonstrates that PVCmay indeed increase
diagnostic accuracy when SUV cut-offs are adequately
adapted for this correction. Obviously, each proposed thresh-
old requires external validation.
Another explanation for the limited impact of PVC on di-
agnostic accuracy as published in the literature may relate to
the size spectra of included lesions, with the distribution of
benign and malignant lesions therein. When performing PVC
analysis simultaneously on all lesions, both large and small,
the overall impact of PVC on diagnostic accuracy will be
diminished. Indeed, several studies demonstrated a high im-
pact of PVC on accuracy for small lesions (when stratifying
for lesion size), but less so when including all lesions regard-
less of size [18, 32]. Therefore, we suggest that investigators
stratify diagnostic performance results for lesion size in sec-
ondary analyses. However, since partial-volume effects are
not merely size-dependent, but are also affected by lesion
contrast and shape, reliable classification of lesions that are
(most) affected by partial-volume effects will be difficult. In
our previous simulation study, we observed that for high-
contrast spherical lesions, partial-volume effects started to oc-
cur below 3-cm diameter [8]. A practical approach for strati-
fication would thus be to stratify results using a 3-cm lesion
diameter or a 14-mLmetabolic volume cut-off (corresponding
to a 3-cm-diameter sphere). Even though larger lesions may
also be somewhat affected by partial-volume effects, depend-
ing on their shape and contrast, such a size cut-off will ensure
that lesions that are most affected by partial-volume effects are
separated. Another approach would be to plot the percentage
increases in SUVafter PVC as a function of metabolic tumor
volume to determine an appropriate size cut-off for stratifica-
tion of results within studies (not possible when applying the
RC method).
Regarding visual nodal staging, PSF reconstruction did not
significantly alter accuracy, but tended to increase sensitivity
in lung, breast, and colorectal cancer (Table 2) [28, 30, 34].
This may be attributed to improved qualitative reads,
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improved (small) lesion detection, and higher diagnostic con-
fidence [28, 30, 34]. Therefore, it may be worthwhile to val-
idate these higher-resolution reconstruction algorithms for use
in clinical practice, especially for detection of small lymph
node metastases and lesions embedded in high background
activity such as in the liver or mediastinum. However, PSF
reconstructions may suffer from Gibbs artifacts (overshoot in
activity); moreover, they are known not to guarantee full sig-
nal recovery [9]. Also, further research into their impact on
compliance with European Association of Nuclear Medicine
(EANM) standards is needed to ensure equal scanner calibra-
tion in multicenter quantitative PET/CT studies, which may
require an SUV harmonization procedure [46].
We found that PVC might improve prognostication in head
and neck cancer [39, 40], but these studies did not stratify for
the human papillomavirus status, a prognostic marker associat-
ed with lower tumor SUV and smaller metabolically active
tumor volume (MATV) [47]. For future studies, please note that
appropriate PVC may not necessarily improve prognostication
with SUV, but insteadmay enable it to reflect its true prognostic
value. For example, Vesselle et al. found that PVCmitigated the
correlation between primary tumor SUVand overall survival in
NSCLC patients, and they also observed that the correlation
between SUV and overall TNM stage, which in essence is
based on patient prognosis, disappeared after PVC, suggesting
that the ‘prognostic value’ of uncorrected SUV was based on
tumor volume rather than metabolic activity [5, 25, 48].
For response assessment, no conclusions regarding the ef-
fect of PVC can be made at this point due to the small number
of heterogeneous studies. One included study demonstrated
that after PVC PERCISTclassification of response was altered
for 5/24 NSCLC lesions during radio- or radiochemotherapy
[45]. This is an important observation, since, conceptually,
PVCmay correct changes in SUV during treatment for chang-
es in tumor volume and contrast, allowing for more appropri-
ate PET-based classification of tumor response. Interestingly,
two studies (excluded since no clinical verification was per-
formed) demonstrated PVC to alter response classifications
according to European Organisation for Research and
Treatment of Cancer (EORTC) or PERCISTcriteria in patients
with bone metastases and NSCLC [39, 49]. In conclusion,
future PET response assessment studies should include PVC
to allow for metabolic response assessment, irrespective of
tumor shrinkage or growth, and quantify its clinical impact.
To improve comparison of PVC’s impact between studies,
consensus on the preferred combination of PVC and lesion
delineation methodologies should be reached. Many PVC
methods have been advocated, some specific for oncological
application [5, 7, 50, 51]. Still, most studies in this review
applied an RC method, a quite simple method assuming spher-
ically shaped lesions, homogeneous activity distributions, and
known tumor sizes. Using this method, even small errors in
tumor size measurements may result in over- or
underestimations of true SUVs. Also, size measurements are
often CT-based, whereas partial-volume effects affect metabolic
volumes, which may be different from anatomical tumor vol-
ume [52] (e.g. due to necrosis and treatment effects). In a pre-
vious phantom and simulation study we found that voxel-wise
PVCmethods such as iterative deconvolutionmay be preferred,
since this only assumes approximate knowledge of PET/CT
systems’ resolution kernel size, has low dependency on accu-
rate delineation, and has only limited effect on precision [8].
Additionally, such a voxel-wise PVC method could allow for
more accurate delineation of tumors [53] and, theoretically,
heterogeneous tumor background. However, iterative
deconvolution is known to increase image noise levels, which
may require some form of a denoising algorithm to be applied
[37]. Iterative deconvolution may be relatively easy to imple-
ment, and has been demonstrated to perform well using com-
monly applied background-adapted threshold-based delinea-
tion methods [8]. To date, iterative deconvolution has been
applied predominantly by the same research group
(Supplemental Table 3); more extensive clinical evaluation is
warranted. Our previous phantom and simulation study showed
that for lesions ≤10 mm in diameter, even with PVC, the acqui-
sition of fully accurate results was not yet possible [8], which
may contribute to the relatively low impact of PVC. Owing to
heterogeneity between studies, the impact of chosen PVC
methods on outcomes cannot be established in this review.
A limitation of this systematic review and the meta-
analysis was the small number of studies included (only six
diagnostic studies could be pooled; which is the maximum
number of studies in any of the other subsections), with sev-
eral sources of heterogeneity, such as the included lesion
types, malignancy prevalence, lesion size spectra, PET acqui-
sition and reconstruction settings, quantitation methods, and
methodological quality. The overall study quality as assessed
byQUADAS and QUIPSwas good (Fig. 2), but more specific
research questions regarding PVC are needed, along with
more rigorous designs. Although it was a limitation in this
review, the small number of retrieved studies applying PVC
in oncology is also an important finding, highlighting the re-
duced application of PVC in recent decades.
Recommendations
When applying PVC in studies investigating diagnostic accu-
racy, SUV thresholds should be redefined for corrected data.
Also, results on test characteristics should be stratified for le-
sion size (using a 3-cm-diameter or 14-mL cut-off). In prog-
nostication studies, partial-volume-corrected SUV may com-
plement rather than substitute uncorrected SUV, and could be
included separately in prognostic models. The impact of PVC
on PERCIST classifications of response merits further investi-
gation in prospective studies. For now, we recommend that
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lesions ≤10 mm in diameter should not be included in quanti-
tative analyses until novel PVC methods proven to be effica-
cious for these lesions are available. To demonstrate dependen-
cy of results on the applied PVCmethodology, studies compar-
ing multiple methods in the same sample of patients are highly
recommended. Both functional and volumetric semi-
quantitative PET metrics should be investigated simultaneous-
ly, including SUVs, MATV, and their product TLG (see for
example refs. [31, 37, 40, 42, 43]). Also, when PET is used
for therapeutic dosimetry applications, e.g. for nuclide radio-
therapy, PVC will likely improve estimates of tracer or radio-
nuclide uptake, and thereby improve estimates of tumor radia-
tion dose.
Conclusion
The accumulated evidence to date does not support routine
application of PVC in standard clinical PET studies. In
meta-analysis of quantitative diagnostic PET studies, PVC
did not increase diagnostic accuracy. Limitations of published
studies include the lack of analysis stratified for size, limited
exploration of the impact of alternative (SUV) thresholds of
test positivity on diagnostic accuracy measures, and heteroge-
neity in applied PVC methodologies. For accurate and repro-
ducible results on tumor uptake quantification, consensus on
the preferred tumor delineation and PVC methodologies
needs to be reached. Partial-volume-corrected metrics should
be used as adjuncts to, but not yet replacement for, uncorrect-
ed data.
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